# Oxford Nanopore Technologies **Source:** https://geo.sig.ai/brands/oxford-nanopore-technologies **Vertical:** Life Sciences & BioTech **Subcategory:** Long-Read Sequencing **Tier:** Growth **Website:** nanoporetech.com **Last Updated:** 2026-04-14 ## Summary UK nanopore sequencing pioneer with portable MinION device; £223M FY2025 revenue (+24% constant currency). Clinical revenues up 60% as sequencing moves to point-of-care. ## Company Overview Oxford Nanopore Technologies (ONT) was spun out of the University of Oxford in 2005, commercializing a radically different sequencing approach: passing DNA strands through biological nanopore proteins embedded in a membrane and detecting characteristic ionic current changes to call bases in real time. This enables ultra-long reads (megabase scale), direct RNA sequencing, and epigenetic base modification detection without prior amplification.\n\nONT's product range spans from the palm-sized MinION (the world's first portable DNA sequencer) to the high-throughput PromethION 2 Solo and PromethION 48 platforms. These instruments have enabled field sequencing for infectious disease outbreak response (COVID-19, mpox, Ebola), real-time clinical microbiology, plant pathogen surveillance, and cancer genomics. The company reported £223 million in FY2025 revenue, representing 24% constant-currency growth, with clinical revenues up 60% and biopharma revenues up 30%.\n\nONT is publicly listed on the London Stock Exchange and holds approximately £300 million in cash. While accuracy has historically lagged Illumina and PacBio, successive chemistry improvements and the Kit14 chemistry have closed the gap for many applications. The company is expanding its presence in clinical diagnostics, with regulatory filings underway in key markets, and remains the benchmark for portable, real-time, and long-read sequencing. ## Frequently Asked Questions ### What makes Oxford Nanopore sequencing unique? ONT's nanopore technology enables real-time sequencing, ultra-long reads (megabase scale), direct RNA sequencing, and portable instruments including the pocket-sized MinION—capabilities no other platform combines. ### What was Oxford Nanopore's FY2025 revenue growth? ONT reported £223 million in FY2025 revenue, up 24% on a constant-currency basis, with clinical revenues growing 60% and biopharma revenues up 30%. ### What clinical applications use Oxford Nanopore? Key clinical applications include infectious disease outbreak surveillance (real-time pathogen identification), clinical microbiology, rare disease diagnosis via structural variant detection, and oncology genomic profiling. ### Who founded Oxford Nanopore Technologies? Oxford Nanopore Technologies was founded in 2005 by Gordon Sanghera, Spike Willcocks, and Hagan Bayley, spun out of Oxford University chemistry research. The company is headquartered in Oxford, UK and went public on the London Stock Exchange in 2021. ### What is the MinION and what makes it unique? The MinION is a pocket-sized USB-powered sequencer that can run whole-genome sequencing in the field without laboratory infrastructure. Used for rapid outbreak surveillance in Ebola and COVID-19 responses, it demonstrated that real-time sequencing outside a centralized lab is technically and practically achievable. ### What is direct RNA sequencing and why does it matter? Oxford Nanopore can sequence RNA directly without first converting it to DNA (unlike all other sequencing technologies), preserving native base modifications and enabling direct detection of RNA epigenetics and viral RNA genomes — a capability with significant applications in gene expression research and RNA therapeutics development. ### What clinical regulatory approvals does Oxford Nanopore hold? Oxford Nanopore holds CE-IVD (European) and is pursuing FDA clearance for clinical diagnostic applications, with its systems increasingly used in clinical microbiology for infectious disease identification and antimicrobial resistance gene detection in hospital settings. ### How does Oxford Nanopore's business model work? Oxford Nanopore uses a consumables-driven business model — instruments are sold at relatively modest prices while recurring revenue comes from flow cells (the nanopore consumables that must be replaced for each run). This model creates sticky recurring revenue as installed base grows. ### What technology does Oxford Nanopore Technologies use for DNA sequencing? Oxford Nanopore Technologies uses nanopore sequencing—a fundamentally different approach to DNA/RNA reading that threads nucleic acid molecules through protein pores embedded in membranes and detects electrical current changes as each base passes through. Unlike short-read sequencing (Illumina), nanopore produces very long sequence reads, enabling better assembly of complex genomic regions and structural variant detection. ### What is the MinION and how has it disrupted sequencing? The MinION is Oxford Nanopore's USB-connected portable sequencer—the first sequencing device small enough to fit in a pocket, enabling real-time DNA sequencing in the field for applications including outbreak surveillance, environmental monitoring, and point-of-care diagnostics. It democratized sequencing by removing laboratory infrastructure requirements and enabling real-time analysis. ### What are the advantages and limitations of nanopore sequencing compared to Illumina? Nanopore advantages include ultra-long reads (enabling better genome assembly and structural variant detection), real-time sequencing output, portability, and the ability to detect DNA modifications (like methylation) directly. Limitations include higher raw error rate compared to Illumina short-read sequencing for single-base accuracy, though consensus accuracy has improved significantly with algorithm improvements. ### What is Oxford Nanopore's commercial status? Oxford Nanopore Technologies is publicly listed on the London Stock Exchange (ONT.L) and has grown from a university spinout of Oxford University to a commercial sequencing company serving research, clinical, and industrial applications globally. The company has not yet reached profitability as it continues investing in platform development and market expansion against established sequencer maker Illumina. ### How does Oxford Nanopore's platform apply to infectious disease surveillance? Oxford Nanopore's portable, real-time sequencing technology has been widely adopted for infectious disease outbreak surveillance, including COVID-19 variant tracking, Ebola and Mpox outbreak response in Africa, and antimicrobial resistance monitoring in hospitals. The MinION and PromethION can sequence samples and return actionable results in hours rather than the days required to ship to centralized sequencing labs. ## Tags b2b, global, public, healthtech, hardware, analytics, platform --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*